Drug Type Small molecule drug |
Synonyms 2-Methyspiro(1,3-oxathiolane-5,3)quinuclidine, Cevimeline, Cevimeline hydrochloride (USAN) + [16] |
Target |
Mechanism M3 receptor agonists(Muscarinic acetylcholine receptor M3 agonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date US (11 Jan 2000), |
Regulation- |
Molecular FormulaC20H38Cl2N2O3S2 |
InChIKeyZSTLCHCDLIUXJE-OFJNZLMZSA-N |
CAS Registry153504-70-2 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D00661 | Cevimeline Hydrochloride |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Sjogren's Syndrome | JP | 20 Jun 2001 | |
Sjogren's Syndrome | JP | 20 Jun 2001 | |
Sjogren's Syndrome | JP | 20 Jun 2001 | |
Antisynthetase Syndrome | US | 11 Jan 2000 | |
Xerostomia | US | 11 Jan 2000 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Crouzon Syndrome With Acanthosis Nigricans | NDA/BLA | CA | 12 Sep 2022 | |
Complication | Phase 3 | US | 01 Jun 2001 | |
Head and Neck Neoplasms | Phase 3 | US | 01 Jun 2001 | |
Toxicity | Phase 3 | US | 01 Jun 2001 | |
Alzheimer Disease | Phase 3 | JP | - | |
Dry Eye Syndromes | Phase 2 | AU | 15 Nov 2024 | |
Dry Eye Syndromes | Phase 2 | TW | 15 Nov 2024 | |
Dementia | Phase 2 | JP | - |
Not Applicable | 15 | (Cevimeline) | jxpimdrywt(qfwruyzxuv) = gebrpmgnku xmvqznamxf (aaxygzfpbh, szvmcoxrth - ufmaxsvmpg) View more | - | 06 Aug 2014 | ||
(Pilocarpine) | jxpimdrywt(qfwruyzxuv) = jajjakqmpi xmvqznamxf (aaxygzfpbh, ohbnujxokj - xgkccsypdg) View more |